OBJECTIVE: To assess the role of chorioamnionitis (CAM) on pregnancy outcome in HIV-1-infected (HIV-positive) pregnant women, treated for sexually transmitted diseases (STDs), during the last trimester of pregnancy in Kigali, Rwanda. METHODS: At inclusion in a prospective cohort, from July 1992 to August 1993, 561 pregnant women between 24 and 28 weeks were systematically screened for HIV infection, STDs, anemia, malaria, and hepatitis B infection; a CD4 lymphocyte count was performed. Until delivery, each woman enrolled had a monthly clinical follow-up with STD treatment when needed. The pregnancy outcome was recorded. Diagnosis of CAM was based on histologic examination of the placenta. RESULTS: Among the 275 placentas of HIV-negative women and 286 placentas of HIV-positive women examined, CAM was diagnosed (CAM-positive) in 27 HIV-positive women (9.8%) and in 28 HIV-negative women (9.8%). No statistical association was found between CAM and the following variables, independent of the HIV serostatus: age, parity, hepatitis B, anemia, STDs, and immune deficiency. Among HIV-negative women, CAM was significantly associated with prematurity (relative risk [RR] = 3.0; 95% confidence interval [CI] = 1.5-6.3), stillbirth (RR = 4.2; 95% CI = 1.6-11.0) and premature rupture of membranes (RR = 2.9; 95% CI = 1.4-6.1). Among HIV-positive women, early neonatal mortality was the only adverse outcome associated with CAM (RR = 2.0; 95% CI = 1.6-11.0). CONCLUSIONS: In our study, the prevalence of CAM was low and no risk factor of CAM was identified, a probable consequence of the control factor of STDs. CAM was strongly associated with adverse pregnancy outcomes in HIV-infected women, reflecting a possible deleterious effect of HIV.
OBJECTIVE: To assess the role of chorioamnionitis (CAM) on pregnancy outcome in HIV-1-infected (HIV-positive) pregnant women, treated for sexually transmitted diseases (STDs), during the last trimester of pregnancy in Kigali, Rwanda. METHODS: At inclusion in a prospective cohort, from July 1992 to August 1993, 561 pregnant women between 24 and 28 weeks were systematically screened for HIV infection, STDs, anemia, malaria, and hepatitis B infection; a CD4 lymphocyte count was performed. Until delivery, each woman enrolled had a monthly clinical follow-up with STD treatment when needed. The pregnancy outcome was recorded. Diagnosis of CAM was based on histologic examination of the placenta. RESULTS: Among the 275 placentas of HIV-negative women and 286 placentas of HIV-positive women examined, CAM was diagnosed (CAM-positive) in 27 HIV-positive women (9.8%) and in 28 HIV-negative women (9.8%). No statistical association was found between CAM and the following variables, independent of the HIV serostatus: age, parity, hepatitis B, anemia, STDs, and immune deficiency. Among HIV-negative women, CAM was significantly associated with prematurity (relative risk [RR] = 3.0; 95% confidence interval [CI] = 1.5-6.3), stillbirth (RR = 4.2; 95% CI = 1.6-11.0) and premature rupture of membranes (RR = 2.9; 95% CI = 1.4-6.1). Among HIV-positive women, early neonatal mortality was the only adverse outcome associated with CAM (RR = 2.0; 95% CI = 1.6-11.0). CONCLUSIONS: In our study, the prevalence of CAM was low and no risk factor of CAM was identified, a probable consequence of the control factor of STDs. CAM was strongly associated with adverse pregnancy outcomes in HIV-infectedwomen, reflecting a possible deleterious effect of HIV.
Authors: H Behbahani; E Popek; P Garcia; J Andersson; A L Spetz; A Landay; Z Flener; B K Patterson Journal: Am J Pathol Date: 2000-12 Impact factor: 4.307
Authors: Amaka N Ocheke; Patricia A Agaba; Godwin E Imade; Olugbenga A Silas; Olanrewaju I Ajetunmobi; Godwins Echejoh; Clement Ekere; Ayuba Sendht; James Bitrus; Emmanuel I Agaba; Atiene S Sagay Journal: Int J STD AIDS Date: 2015-04-16 Impact factor: 1.359
Authors: Hayley R Price; Nick Pang; Hugh Kim; Michael W H Coughtrie; Abby C Collier Journal: J Assist Reprod Genet Date: 2022-01-06 Impact factor: 3.412
Authors: Roger L Shapiro; Sajini Souda; Natasha Parekh; Kelebogile Binda; Mukendi Kayembe; Shahin Lockman; Petr Svab; Orphinah Babitseng; Kathleen Powis; William Jimbo; Tracy Creek; Joseph Makhema; Max Essex; Drucilla J Roberts Journal: PLoS One Date: 2012-02-22 Impact factor: 3.240
Authors: John Ategeka; Razack Wasswa; Peter Olwoch; Abel Kakuru; Paul Natureeba; Atis Muehlenbachs; Moses R Kamya; Grant Dorsey; Gabrielle Rizzuto Journal: PLoS One Date: 2019-04-11 Impact factor: 3.240
Authors: Moses M Obimbo; Yan Zhou; Michael T McMaster; Craig R Cohen; Zahida Qureshi; John Ong'ech; Julius A Ogeng'o; Susan J Fisher Journal: J Acquir Immune Defic Syndr Date: 2019-01-01 Impact factor: 3.731
Authors: Aung Myat Min; Makoto Saito; Julie A Simpson; Stephen H Kennedy; François H Nosten; Rose McGready Journal: PLoS One Date: 2021-08-12 Impact factor: 3.240